HC Wainwright reaffirmed their buy rating on shares of Indaptus Therapeutics (NASDAQ:INDP – Free Report) in a research note issued to investors on Monday, Benzinga reports. They currently have a $12.00 price target on the stock. HC Wainwright also issued estimates for Indaptus Therapeutics’ Q1 2024 earnings at ($0.57) EPS, Q2 2024 earnings at ($0.60) […]
Indaptus Therapeutics (INDP) Presents Positive Mechanism of Action Data streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.